Clinical Trial Update: Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating upfront CAR-T cell therapy to upgrade response in multiple myeloma; results have been posted for this completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2026-01-12